Sucralfate: Nursing Drug Guide, Drug Binding & NCLEX Review

Sucralfate is widely known by the brand name Carafate (CARAFATE tablets and oral suspension per DailyMed labeling). Generic sucralfate tablets and suspension are available. Because sucralfate is a local-acting mucosal protectant—not a systemic acid suppressant—nurses must not confuse it with PPIs or H2 blockers during medication reconciliation.

Verify formulation (tablet vs suspension), dose in grams, and scheduled empty-stomach times on every MAR pass. A patient may carry home Carafate while also receiving inpatient acid-suppression therapy—each drug class has different administration rules.

Sucralfate is indicated for short-term treatment (up to 8 weeks) of active duodenal ulcer and for maintenance therapy after duodenal ulcer has healed, per CARAFATE prescribing information. Symptomatic relief does not exclude gastric malignancy—persistent alarm symptoms require diagnostic follow-up per prescriber plan.

↔On a small screen, swipe or scroll sideways to see the full table.

Pediatric safety and effectiveness have not been established per prescribing information. Not specified in the reviewed prescribing information for erosive esophagitis or GERD as primary labeled indications—verify prescriber intent against current labeling.

Sucralfate is a basic aluminum salt of sucrose octasulfate. In an acidic environment it forms a viscous paste that adheres to ulcer craters and damaged mucosa, creating a protective barrier against acid, pepsin, and bile. Only a small fraction is systemically absorbed—most activity is local in the GI tract per labeling. That local binding property is also what traps other oral drugs in the stomach and duodenum, which is why the 2-hour separation rule is a core nursing safety task rather than a minor scheduling detail.

Adult oral dosing depends on whether the patient is treating an active duodenal ulcer or on maintenance therapy. All doses should be taken on an empty stomach per CARAFATE labeling. Dosing must be verified against current prescribing information, prescriber order, renal function, and local policy.

Renal adjustment: No specific dose reduction is listed in the reviewed prescribing information, but labeling warns that aluminum is eliminated in urine and may accumulate in patients with chronic renal failure or on dialysis—use caution and coordinate with pharmacy. Missed dose: Not specified in the reviewed prescribing information; follow prescriber or pharmacy guidance and do not double doses.

Pretreatment checks

• Confirm oral route only—never IV, IM, or subcutaneous; IV administration has caused fatal emboli per labeling
• Verify empty-stomach timing: 1 hour before or 2 hours after meals
• Review MAR for interacting oral drugs—stagger at least 2 hours before sucralfate per labeling
• Check renal function in patients with chronic kidney disease or dialysis—aluminum accumulation risk
• Assess swallowing ability; aspiration caution with tablets in patients with swallowing impairment per labeling

Contraindications

• Known hypersensitivity to sucralfate or formulation excipients per labeling

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Route: Oral tablet or oral suspension only per CARAFATE labeling. Never administer intravenously—fatal emboli have been reported with IV use.

• Give on an empty stomach—1 hour before or 2 hours after meals
• Active ulcer: 1 g four times daily; maintenance: 1 g twice daily
• Swallow tablets whole with water; shake suspension well before each dose per labeling
• Antacids may be used PRN for pain relief but not within 30 minutes before or after sucralfate
• Stagger all other oral medications at least 2 hours before sucralfate
• Use aspiration precautions and consider suspension when swallowing is impaired

• Decrease in epigastric discomfort when used for duodenal ulcer symptoms—healing is assessed by prescriber and endoscopy, not at the bedside alone
• Reduced need for PRN antacids when ulcer symptoms improve, provided antacids are separated by 30 minutes from sucralfate
• Stable bowel pattern—monitor for sucralfate-associated constipation per labeling
• No clinical signs of interacting drug failure when 2-hour separation is maintained—stable INR on warfarin, no breakthrough infection on fluoroquinolones, stable thyroid status on levothyroxine

Stop sucralfate and escalate when aspiration, aluminum toxicity, serious hypersensitivity, or interacting-drug failure is suspected—especially when MAR timing violates the 2-hour separation rule or IV administration is attempted.

• Any attempt to give sucralfate intravenously—hold immediately; IV use has caused fatal emboli per labeling
• Coughing, choking, or respiratory distress after tablet administration in a patient with swallowing impairment—suspect aspiration
• Rising INR or bleeding on warfarin when doses were given within 2 hours of sucralfate—binding may have reduced anticoagulant effect or caused erratic absorption
• Worsening renal function in a patient on dialysis or advanced CKD—reassess aluminum toxicity risk; trend serum creatinine
• Severe rash, angioedema, bronchospasm, or anaphylaxis—discontinue and initiate emergency pathway per protocol
• Persistent abdominal pain, melena, or hematemesis despite therapy—may signal ulcer complication or malignancy
• Breakthrough seizures on phenytoin or hypothyroid symptoms on levothyroxine after sucralfate timing errors

↔On a small screen, swipe or scroll sideways to see the full table.

Because sucralfate is minimally absorbed from the GI tract, acute overdose is unlikely to produce systemic toxicity per CARAFATE labeling. Overdose experience is limited in the reviewed prescribing information.

Management

• No specific antidote is listed in the reviewed prescribing information
• Treatment is symptomatic and supportive
• Monitor for constipation, bezoar risk, and signs of aluminum toxicity in patients with renal impairment

• Sucralfate vs sucrose / sulfasalazine—verify drug name and indication on every pass
• Carafate vs other “-fate” or “-ate” GI drugs—confirm mucosal protectant vs acid suppressant
• Tablet vs suspension—dysphagia patients need correct formulation to reduce aspiration risk
• 1 g vs 100 mg—gram-based dosing is unusual; read label and barcode carefully
• Oral vs IV route errors—never administer sucralfate IV; fatal emboli reported per labeling
• Simultaneous MAR times—sucralfate scheduled with warfarin or levothyroxine at the same hour is a high-risk binding error

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• MAR timing—confirm 2-hour separation from interacting oral drugs at each medication pass
• Renal function in CKD/dialysis—trend BMP and aluminum toxicity signs when clinically indicated
• INR and bleeding when warfarin is co-administered with staggered timing
• GI symptoms—ulcer pain relief, stool pattern, constipation, and alarm features
• Swallowing and respiratory status when tablets are used in at-risk patients
• Signs of interacting drug failure—breakthrough infection on fluoroquinolones, hypothyroid symptoms, seizure activity on phenytoin

Document

• Empty-stomach verification and actual administration time relative to meals
• Pharmacy coordination when MAR times are rebuilt for 2-hour separation
• Formulation (tablet vs suspension) and aspiration precautions when applicable
• Patient education on timing rules and why sucralfate must not be given IV

• Take sucralfate on an empty stomach—1 hour before or 2 hours after eating
• Take your other medicines at least 2 hours before sucralfate unless pharmacy gives different instructions
• Do not take antacids within 30 minutes before or after sucralfate
• This medicine is swallowed only—never injected
• Report constipation that is severe or does not improve, trouble swallowing tablets, or coughing when taking doses
• Report black stools, vomiting blood, or severe abdominal pain—these are not normal ulcer symptoms
• Seek urgent care for severe rash, facial swelling, or trouble breathing

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Rehearse NCLEX-style clinical judgment practice for sucralfate using a tabbed case panel (MAR, labs, history, nursing notes), then priority action, cue recognition (SATA), INR trend interpretation after binding errors, documentation cloze, ordered administration steps, and matrix urgency matching—recognise drug-binding and empty-stomach cues → analyse MAR overlap → prioritise → act → evaluate outcomes when INR drifts after sucralfate is given too close to warfarin.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.